Recent studies have found that CCT2 is critical for the survival of breast cancer patients, and is significantly higher in hepatocellular carcinoma, colon cancer, extrahepatic cholangiocarcinoma, gallbladder cancer, and gastric cancer than benign lesions and normal tissues. Here, CCT2 is linked to colonic neoplasm.